Roundtable Discussion: Unlocking Therapeutic Opportunity in MMN & GBS Through Improved Understanding of Disease Biology & Timing
- How can refining diagnosis, prevalence understanding and immune drivers (e.g. complement and autoantibodies) in MMN uncover a clearer therapeutic opportunity, enabling companies to confidently expand beyond MG into an underrecognised but potentially high-value market?
- What defines the true biological window of intervention in GBS, and how can aligning immune modulation strategies to disease phase (rather than late-stage symptoms) improve clinical outcomes and prevent irreversible damage?
- How should evolving insights into MMN and GBS pathophysiology reshape trial design, from patient identification to endpoint selection, to ensure therapies demonstrate meaningful efficacy within the right population and timing?